The antibody drug conjugates market is projected to grow at an annualized rate of over 20%

Roots Analysis has done a detailed report on Antibody Drug Conjugates Market, covering various important aspects of the industry and identifying key future growth opportunities.
To order this 600+ page report, which features 190+ figures and 280+ tables, please visit this link
Key Market Insights 
  • Eminent representatives from different biopharmaceutical companies confirm the sustained interest in ADC therapeutics, highlighting the technological innovation that is driving contemporary R&D initiatives
  • Presently, over 240 ADC therapy candidates are being evaluated in clinical / preclinical stages for treating a variety of solid tumors / hematologic cancers
  • The pipeline features product candidates that target a wide range of biological antigens and are equipped with different cytotoxic warheads; a number of companies are focused on developing novel drug conjugates
  • In order to gain a competitive edge in the market, ADC developers are actively exploring new biological targets, conducting clinical trials across different geographies to treat diverse disease indications
  • A number of eminent scientists from renowned universities, owing to their involvement in clinical development efforts, have emerged as key opinion leaders within this market
  • Over the years, more than 16,000 patents related to ADCs have been filed / granted across the world, indicative of the ongoing pace of R&D activity in this field of research
  • Several investors, having realized the opportunity within this upcoming segment of targeted cancer therapeutics industry, have invested over USD 5 billion, in the period between 2011 and 2019
  • The increasing interest in this field is also reflected in the partnership activity; deals inked in the recent past were mostly focused on licensing of products / technologies, involving both international and indigenous stakeholders
  • In the recent years, several developer companies have initiated clinical trials to evaluate the therapeutic potential of ADCs in combination with other drug / therapy classes
  • Anticipating the launch of several product candidates, stakeholders are exploring diverse commercialization strategies across different stages of the launch cycle along with the appropriate reimbursement strategies
  • Given the complexities associated with the development and production of ADCs, CMOs are indispensable to the R&D and manufacturing activity in this domain; some CMOs have even pioneered the novel ADC technology platforms
  • Case Study: In order to keep patients and healthcare professionals informed and aware of the developments, companies are deploying diverse promotional strategies for their respective products
  • With a promising development pipeline and encouraging clinical results, the global market is anticipated to witness growth at an annualized rate of over 20% during the next decade
  • The anticipated future opportunity is likely to be distributed across different types of linkers and target antigens as more late-stage drugs get commercialized and existing marketing authorizations are expanded
For more information, please visit https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html
 
Table of Contents
 
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. Evolution of Anticancer Therapy
3.3. Cancer Treatment Methods
3.3.1. Surgery
3.3.2. Radiation Therapy
3.3.3. Chemotherapy
3.3.4. Targeted Therapies
 
3.4. Monoclonal Antibody-Based Anticancer Therapies
3.5. Components of Antibody Drug Conjugates (ADCs)
3.5.1. Antibody
3.5.2. Cytotoxin
3.5.3. Linker
 
3.6. Advantages of ADC Therapeutics over Traditional Therapeutic Interventions
3.7. Differences Between Small Molecule Drugs, Monoclonal Antibody Therapies and ADCs
3.8. Pharmacokinetic Properties of ADCs
3.8.1. Absorption
3.8.2. Distribution
3.8.3. Metabolism and Excretion
 
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. ADC Therapeutics: Clinical Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Indication
4.2.3. Analysis by Line of Treatment
4.2.4. Analysis by Dosing Regimen
4.2.5. Analysis by Type of Therapy
4.2.6. Analysis by Target Antigen
4.2.7. Analysis by Antibody Origin
4.2.8. Analysis by Antibody Isotype
4.2.9. Analysis by Type of Linker
4.2.10. Analysis by Type of Payload / Warhead
4.2.11. Key Technology Providers
4.2.12. Discontinued Drugs
 
4.3. ADC Therapeutics: Preclinical Pipeline
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Indication
4.3.3. Analysis by Target Antigen
4.3.4. Key Players: Analysis by Number of ADC Therapeutics
 
4.4. ADC Therapeutics: Developer Landscape
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Geographical Location
4.4.4. Logo Landscape: Analysis by Size and Target Indication
4.5. Novel Drug Conjugates
 
5. COMPANY AND DRUG PROFILES
5.1. Chapter Overview
5.2. AbbVie
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Pipeline Overview
5.2.3.1. Rovalpituzumab Tesirine / ROVA-T
5.2.3.1.1 Drug Overview
5.2.3.1.2. Mechanism of Action
5.2.3.1.3. Clinical Development Status
5.2.3.1.4. Key Clinical Trial Results
 
5.2.3.2. Teliso-V / Telisotuzumab Vedotin / ABBV-399
5.2.3.2.1 Drug Overview
5.2.3.2.2. Mechanism of Action
5.2.3.2.3. Clinical Development Status
5.2.3.2.4. Key Clinical Trial Results
5.2.4. Recent Developments and Future Outlook
 
5.3. Astellas Pharma
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Pipeline Overview
5.3.3.1. Enfortumab Vedotin
5.3.3.1.1. Drug Overview
5.3.3.1.2. Mechanism of Action
5.3.3.1.3. Clinical Development Status
5.3.3.1.4. Key Clinical Trial Results
 
5.3.3.2. ASG16-M8F
5.3.3.2.1. Drug Overview
5.3.3.2.2. Mechanism of Action
5.3.3.2.3. Clinical Development Status
5.3.3.2.4. Key Clinical Trial Results
5.3.4. Recent Developments and Future Outlook
5.4. AstraZeneca
54.1. Company Overview
5.4.2. Financial Information
5.4.3. Pipeline Overview
5.4.3.1. LUMOXITI™
5.4.3.1.1. Drug Overview
5.4.3.1.2. Mechanism of Action
5.4.3.1.3. Clinical Development Status
5.4.3.1.4. Key Clinical Trial Results
5.4.4. Recent Developments and Future Outlook
 
5.5. Daiichi Sankyo
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Pipeline Overview
5.5.3.1. Trastuzumab deruxtecan / DS-8201a / DS 8201
5.5.3.1.1. Drug Overview
5.5.3.1.2. Mechanism of Action
5.5.3.1.3. Clinical Development Status
5.5.3.1.4. Key Clinical Trial Results
5.5.4. Recent Developments and Future Outlook
 
5.6. ImmunoGen
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Pipeline Overview
5.6.3.1. IMGN853 / Mirvetuximab soravtansine
5.6.3.1.1. Drug Overview
5.6.3.1.2. Mechanism of Action
5.6.3.1.3. Clinical Development Status
5.6.3.1.4. Key Clinical Trial Results
5.6.4. Recent Developments and Future Outlook
5.7. Immunomedics
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Pipeline Overview
5.7.3.1. IMMU-130
5.7.3.1.1. Drug Overview
5.7.3.1.2. Mechanism of Action
5.7.3.1.3. Clinical Development Status
5.7.3.1.4. Key Clinical Trial Results
5.7.4. Recent Developments and Future Outlook
 
5.8. Pfizer
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Pipeline Overview
5.8.3.1. CMC-544 / BESPONSA® / Inotuzumab Ozogamicin
5.8.3.1.1. Drug Overview
5.8.3.1.2. Mechanism of Action
5.8.3.1.3. Clinical Development Status
5.8.3.1.4. Key Clinical Trial Results
 
5.8.3.2. MYLOTARG™ / Gemtuzumab Ozogamicin
5.8.3.2.1. Drug Overview
5.8.3.2.2. Mechanism of Action
5.8.3.2.3. Clinical Development Status
5.8.3.2.4. Key Clinical Trial Results
5.8.4. Recent Developments and Future Outlook
 
5.9. Roche / Genentech
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Pipeline Overview
5.9.3.1. KADCYLA®
5.9.3.1.1. Drug Overview
5.9.3.1.2. Mechanism of Action
5.9.3.1.3. Clinical Development Status
5.9.3.1.4. Key Clinical Trial Results
 
5.9.3.2. RG-7596
5.9.3.2.1. Drug Overview
5.9.3.2.2. Mechanism of Action
5.9.3.2.3. Clinical Development Status
5.9.3.2.4. Key Clinical Trial Results
5.9.4. Recent Developments and Future Outlook
 
5.10. Seattle Genetics
5.10.1. Company Overview
5.10.2. Financial Information
5.10.3. Pipeline Overview
5.10.3.1. ADCETRIS®
5.10.3.1.1. Drug Overview
5.10.3.1.2. Mechanism of Action
5.10.3.1.3. Clinical Development Status
5.10.3.1.4. Key Clinical Trial Results
 
5.10.3.2. SGN- LIV1A
5.10.3.2.1. Drug Overview
5.10.3.2.2. Mechanism of Action
5.10.3.2.3. Clinical Development Status
5.10.3.2.4. Key Clinical Trial Results
5.10.4. Recent Developments and Future Outlook
 
5.11. Synthon
5.11.1. Company Overview
5.11.2. Financial Information
5.11.3. Pipeline Overview
5.11.3.1. SYD985 / Trastuzumab Duocarmazine
5.11.3.1.1. Drug Overview
5.11.3.1.2. Mechanism of Action
5.11.3.1.3. Clinical Development Status
5.11.3.1.4. Key Clinical Trial Results
5.11.4. Recent Developments and Future Outlook
 
5.12. Other Companies
5.12.1. Bayer HealthCare
5.12.1.1. Company Overview
5.12.1.2. Financial Information
5.12.1.3. Pipeline Overview
5.12.1.4. Recent Developments and Future Outlook
 
5.12.2. Biotest Pharmaceuticals
5.12.2.1. Company Overview
5.12.2.2. Financial Information
5.12.2.3. Pipeline Overview
5.12.2.4. Recent Developments and Future Outlook
 
6. KEY THERAPEUTIC AREAS
6.1. Chapter Overview
6.2. Hematological Malignancies
6.2.1. Leukemias and Lymphomas
6.2.1.1. Leukemia: Introduction and Epidemiology
6.2.1.1.1. Acute Myeloid Leukemia
6.2.1.1.2. Chronic Myeloid Leukemia
6.2.1.1.3. Acute Lymphocytic Leukemia
6.2.1.1.4. Chronic Lymphocytic Leukemia
6.2.1.2. Lymphoma: Introduction and Epidemiology
6.2.1.3. Current Treatment Landscape
6.2.1.4. ADC Therapeutics for Leukemia / Lymphoma
 
6.2.2. Multiple Myeloma
6.2.2.1. Introduction and Epidemiology
6.2.2.2. Current Treatment Landscape
6.2.2.3. ADC Therapeutics for Multiple Myeloma
 
6.3. Solid Tumors
6.3.1. Lung Cancer
6.3.1.1. Introduction and Epidemiology
6.3.1.2. Current Treatment Landscape
6.3.1.3. ADC Therapeutics for Lung Cancer
 
6.3.2. Breast Cancer
6.3.2.1. Introduction and Epidemiology
6.3.2.2. Current Treatment Landscape
6.3.2.3. ADC Therapeutics for Breast Cancer
 
6.3.3. Ovarian Cancer
6.3.3.1. Introduction and Epidemiology
6.3.3.2. Current Treatment Landscape
6.3.3.3. ADC Therapeutics for Ovarian Cancer
 
6.3.4. Bladder Cancer
6.3.4.1. Introduction and Epidemiology
6.3.4.2. Current Treatment Landscape
6.3.4.3. ADC Therapeutics for Bladder Cancer
 
6.3.5. Colorectal Cancer
6.3.5.1. Introduction and Epidemiology
6.3.5.2. Current Treatment Landscape
6.3.5.3. ADC Therapeutics for Colorectal Cancer
 
6.3.6. Prostate Cancer
6.3.6.1. Introduction and Epidemiology
6.3.6.2. Current Treatment Landscape
6.3.6.3. ADC Therapeutics for Prostate Cancer
 
6.3.7. Gastric Cancer
6.3.7.1. Introduction and Epidemiology
6.3.7.2. Current Treatment Landscape
6.3.7.3. ADC Therapeutics for Prostate Cancer
 
7. KEY OPINION LEADERS
7.1. Chapter Overview
7.2. Methodology
 
7.3. Principal Investigators / Sub-Investigators / Study Directors Involved in Clinical Trials
7.3.1. Geographical Distribution of Key Opinion Leaders
7.3.1.1. Experts on ADCETRIS®
7.3.1.2. Experts on KADCYLA®
7.3.1.3. Experts on MYLOTARG™
7.3.1.4. Experts on Other ADCs
 
7.4. Prominent Key Opinion Leaders (KOLs)
7.5. KOL Benchmarking: Roots Analysis versus Third Party Scoring (ResearchGate Score)
 
7.6. Most Active Key Opinion Leaders
7.6.1. Profile: KOL A (Celgene)
7.6.2. Profile: KOL B (Western Regional Medical Center)
7.6.3. Profile: KOL C (MedStar Washington Hospital Center)
7.6.4. Profile: KOL D (Cancer Institute and Hospital)
7.6.5. Profile: KOL E (Comprehensive Cancer Centers of Nevada)
7.6.6. Profile: KOL F (Hopital Tenon)
7.6.7. Profile: KOL G (Cleveland Clinic)
 
8. TARGET COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Competitiveness Analysis: Key Clinical Targets for ADCs
8.3.1. Four-Dimensional Bubble Analysis
8.3.2 Five-Dimensional Spider Web Analysis
 
8.4. Competitiveness Analysis: Key Preclinical Targets for ADCs
8.4.1. Two-Dimensional Scatter Plot Analysis
 
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. ADC Therapeutics: List of Partnerships and Collaborations
9.3.1 Analysis by Year of Partnerships
9.3.2. Analysis by Type of Partnerships
9.3.3. Most Active Players: Analysis by Number of Partnerships
 
9.3.4. Regional Analysis
9.3.4.1. Intercontinental and Intracontinental Agreements
 
10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. ADC Therapeutics: Funding and Investment Analysis
10.3.1. Analysis by Number of Instances
10.3.2. Analysis by Amount Invested
10.3.3. High Value Deals: Analysis by Year
10.3.4. Analysis by Type of Funding
 
10.3.5. Most Active Players
10.3.5.1. Analysis by Number of Funding Instances
10.3.5.2. Analysis by Amount Invested
10.4. Concluding Remarks
 
11. PATENT ANALYSIS
11 Patent Analysis
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. ADC Therapeutics: Patent Analysis
11.3.1. Analysis by Publication Year
11.3.2. Analysis by Geographical Location
11.3.3. Analysis by CPC Classification
11.3.4. Emerging Focus Areas
11.3.5. Analysis by Type of Industry
11.3.6. Leading Players: Analysis by Number of Patents
11.4. ADC Therapeutics: Patent Benchmarking Analysis (Industry Players)
11.4.1. Analysis by Patent Characteristics
11.4.2. Analysis By Geographical Location
11.5. ADC Therapeutics: Patent Valuation Analysis
 
12. ACADEMIC GRANTS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. ADC Therapeutics: List of Academic Grants
12.3.1. Analysis by Number of Grants
12.3.2. Analysis by Type of Grant
12.3.3. Analysis by Grant Amount
12.3.4. Analysis by Focus Area
12.3.5. Analysis by Support Period
 
12.4. Leading Organizations: Analysis by Number of Grants
12.5. Analysis by Type of Recipient Organization
12.6. Analysis by Administering Institute Center
12.7. Analysis by Funding Institute Center
12.8. Key Project Leaders: Analysis by Number of Grants
 
13. KEY COMMMERCIALIZATION STRATEGIES
13.1. Chapter Overview
13.2. Successful Drug Launch Strategy: ROOTS Framework
13.3. Successful Drug Launch Strategy: Product Differentiation
13.4. Common Commercialization Strategies Adopted Based on Development Stage of Product
 
13.5. Approved Molecules for ADCs
13.5.1. ADCETRIS®
13.5.2. KADCYLA®
13.5.3. MYLOTARG™
13.5.4. BESPONSA®
13.5.5. LUMOXITI™
13.5.5. POLIVY™
 
13.6. Key Commercialization Strategies Adopted by Companies Developing ADCs
13.6.1. Strategies Adopted Before Drug Approval
13.6.1.2. Collaboration with Internal Stakeholders and Pharmaceutical Firms
 
13.6.2. Strategies Adopted During / Post Drug Approval
13.6.2.1. Geographical Expansion
13.6.2.2. Participation in Global Events
13.6.2.3. Awareness Through Product Websites
13.6.2.4. Collaboration with Internal Stakeholders and Pharmaceutical Firms
13.7. Concluding Remarks
 
14. PROMOTIONAL ANALYSIS
14.1. Chapter Overview
14.2. Channels Used for Promotional Campaigns
14.3. Summary of Product Website Analysis
14.4. Summary of Patient Brochure and Informative Downloads
 
14.5. ADCETRIS®: Promotional Analysis
14.5.1. Product Website Analysis
14.5.1.1. Messages for Healthcare Professionals
14.5.1.2. Messages For Patients
14.5.2. Patient Support Services and Informative Downloads
14.5.3. Other Promotional Activities
14.5.3.1. Presence in Conferences
 
14.6. KADCYLA®: Promotional Analysis
14.6.1. Product Website Analysis
14.6.1.1. Messages for Healthcare Professionals
14.6.1.2. Messages for Patients
14.6.2. Patient Support Services and Informative Downloads
14.6.3. Other Promotional Activities
14.6.3.1. Presence in Conferences
 
14.7. MYLOTARG™: Promotional Analysis
14.7.1. Product Website Analysis
14.7.1.1. Messages for Healthcare Professionals
14.7.1.2. Messages for Patients
14.7.2. Patient Support Services and Informative Downloads
14.7.3. Other Promotional Activities
14.7.3.1. Presence in Conferences
 
14.8. BESPONSA®: Promotional Analysis
14.8.1. Product Website Analysis
14.8.1.1. Messages for Healthcare Professionals
14.8.1.2. Messages for Patients
14.8.2. Patient Support Services and Informative Downloads
14.8.3. Other Promotional Activities
14.8.3.1. Presence in Conferences
 
14.9. LUMOXITI™: Promotional Analysis
14.9.1. Product Website Analysis
14.9.1.1. Messages for Healthcare Professionals
14.9.1.2. Messages for Patients
14.9.2. Patient Support Services and Informative Downloads
14.9.3. Other Promotional Activities
14.9.3.1. Presence in Conferences
 
14.10. POLIVY™: Promotional Analysis
14.10.1. Product Website Analysis
14.10.1.1. Messages for Healthcare Professionals
14.10.1.2. Messages for Patients
14.10.2. Patient Support Services and Informative Downloads
14.10.3. Other Promotional Activities
14.10.3.1. Presence in Conferences
 
15. COMBINATION THERAPIES
15.1. Chapter Overview
15.2. Combination Therapy: History of Development
15.3. FDA-approved Combination Therapies in Oncology
 
15.4. Combination Therapy: FDA Guidelines
15.4.1. Combinations of Marketed Drugs
15.4.2. Combinations of Marketed Drugs with New Molecular Entities
15.4.3. Combinations of New Molecular Entities
 
15.5. Combination Therapies: ADCs
15.5.1. Completed / Ongoing Clinical Studies of ADCs
15.5.1.1. Analysis by Type of Therapy
15.5.2. Completed / Ongoing Clinical Studies of ADC-based Combination Therapies
15.5.2.1. Analysis by Highest Phase of Development
15.5.2.2. Analysis by Current Trial Status
15.5.2.3. Analysis by Type of Combination
15.5.2.4. Analysis by Indication and Type of Combination
 
16. NOVEL CONJUGATION TECHNOLOGY PLATFORMS
16.1. Chapter Overview
16.2. First Generation ADC Technologies
 
16.3. Second Generation ADC Technologies
16.3.1. Cysteine and Selenocysteine Engineering
16.3.2. Unnatural Amino Acid Engineering
16.3.3. Amino-Terminal Engineered Serine
 
16.4. Third Generation ADC Technologies
16.4.1. Enzyme-Assisted Ligation Approaches
16.4.2. Glycan Remodeling Approaches
16.4.3. Ligation at Fab Nucleotide-Binding Site
16.4.4. Cysteine Rebridging
16.4.5. Preventing / Limiting Retro-Michael Drug Deconjugation
16.5. Evolutionary Analysis of Conjugation Technologies
 
17. ASSESMENT OF NON-CLINICAL DATA, FIRST IN HUMAN DOSING
17.1. Chapter Overview
17.2. ADCs and Non-Clinical Studies
17.3. ICH S9 Guidelines
 
17.4. Investigational New Drug (IND)-Enabling Study Designs
17.4.1. Example Case: KADCYLA®
 
17.5. Toxicities in Animal Models
17.6. Prediction of Maximum Tolerated Dosage (MTD) in Humans
17.7. Other Key Considerations for Study Design
 
18. COST PRICE ANALYSIS

You may also like

Discussion

No comments yet... Be the first to leave a reply! Login here

avatar
BenJ
0 Karma
415 Posts

Made with by Mamby